• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Daiichi Sankyo Ltd (OP: DSKYF )

    27.50 -1.52 (-5.25%)
    Streaming Delayed Price Updated: 10:30 AM EST, Jan 29, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Daiichi Sankyo Ltd

    < Previous 1 2 Next >
    AstraZeneca's Enhertu Wins European Approval For Pretreated Breast Cancer Setting
    Via Benzinga
    The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies
    Via Benzinga
    Morning Brief: Top Financial Stories Dominating on Monday, June 6
    Reuters 
    Via Benzinga
    AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease Progression Or Death Risk By Almost 50%
    Via Benzinga
    FDA Approval For AstraZeneca - Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
    Via Benzinga
    The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer
    Via Benzinga
    The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
    Here's a roundup of top developments in the biotech space over the last 24 hours. 
    Via Benzinga
    Daiichi Sankyo - AstraZeneca's Enhertu Receives Priority Review In US For Lung Cancer
    Via Benzinga
    Seagen Wins $42M Patent Claim Against Daiichi In Cancer Drug Case
    A jury in Marshall, Texas, awarded Seagen Inc (NASDAQ: SGEN)  
    Via Benzinga
    AstraZeneca's Enhertu Meets Primary Endpoint In HER2-Low Breast Cancer Setting
    AstraZeneca plc (NASDAQ: AZN) said that Enhertu prolonged survival and slowed the progression of metastatic breast cancer with low levels of a protein known as HER2... 
    Via Benzinga
    Esperion Chops 40% Workforce As Launch Of Cholesterol Medication Falters
    Esperion Therapeutics Inc's (NASDAQ: ESPR) cholesterol drug marketing strategy has soured badly, as it has been struggling to sell its heart disease pill for more than a... 
    Via Benzinga
    AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
    AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSNKY) Enhertu have shown some striking data in late-stage breast cancer trials and early solid tumor... 
    Via Benzinga
    AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer
    AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu... 
    Via Benzinga
    AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer
    AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo Co Ltd (OTC: DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3... 
    Via Benzinga
    Daiichi Sankyo - AstraZeneca Start Dosing In Head-To-Head Stomach Cancer Trial With Enhertu
    Daiichi Sankyo Co Ltd (OTC: DSKYF) and AstraZeneca plc (NASDAQ: AZN) have dosed the first patient in DESTINY-Gastric04, Phase 3 trial of Enhertu (... 
    Via Benzinga
    Daiichi Sankyo To Stop Testing Inhaled Nafamostat In COVID-19 Patients In Japan
    Daiichi Sankyo Co Ltd (OTC: DSNKY) said it was halting the development of an existing drug for the treatment of COVID-19 without citing a reason. However, the... 
    Via Benzinga
    Exposures COVID-19
    Nipro To Provide Fill, Finish Services For AstraZeneca COVID-19 Shots In Japan: Reuters
    Japan's Nipro Corporation has signed an agreement to supply AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine in Japan, reports Reuters. Nipro... 
    Via Benzinga
    Exposures COVID-19
    AstraZeneca, Daiichi Sankyo Partnered ADC Shows Promise In Hard-To-Treat Breast Cancer
    AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OCTMKTS: DSNKY) have announced an update from their second antibody-drug conjugate (ADC) program... 
    Via Benzinga
    LogicBio Therapeutics, CANbridge Ink Partnership For Development Of Gene Therapy Candidates
    CANbridge Pharmaceuticals Inc has entered into a strategic collaboration and licensing agreement with LogicBio Therapeutics Inc (NASDAQ: LOGC) to... 
    Via Benzinga
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.